1 – 103 of 103
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Governing, Protecting, and Regulating the Future of Genome Editing : The Significance of ELSPI Perspectives
(
- Contribution to journal › Scientific review
-
Mark
Ecosystem effectuation : creating new value through open innovation during a pandemic
(
- Contribution to journal › Article
- 2021
-
Mark
The Role of Patents and Licensing in the Governance of Human Genome Editing: A White Paper
2021)(
- Book/Report › Report
- 2020
-
Mark
An EU Comparative Analysis of the Regulation of Clinical Trials Supervisory Bodies in the Aftermath of Regulation 536/2014
(
- Contribution to journal › Article
-
Mark
Preparing for antimicrobial resistance in the wake of the COVID-19 pandemic: The vision and “social science” mission of the INAMRSS network
2020)(
- Other contribution › Web publication
-
Mark
A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways
(
- Contribution to journal › Article
-
Mark
ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19
(
- Contribution to journal › Article
-
Mark
Knowledge transfer for large scale vaccine manufacturing
(
- Contribution to journal › Article
-
Mark
Applying the Proportionality Principle to COVID-19 Antibody Testing
2020) In Journal of Law and the Biosciences(
- Contribution to journal › Article
-
Mark
AIRR Data Under the E.U. Trade Secrets Directive: Aligning Scientific Practices with Commercial Realities
2020) p.239-268(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Book introduction: An Appraisal of the EU Directive on Trade Secrets
2020) p.1-7(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The harmonization and protection of trade secrets in the EU: – An Appraisal of the EU Directive
2020)(
- Book/Report › Book
-
Mark
When does stand-alone software qualify as a medical device in the European Union?: The CJEU decision in SNITEM and what it implies for the next generation of medical devices
(
- Contribution to journal › Article
-
Mark
Ethical and Legal Challenges of Artificial Intelligence-Driven Health Care
2020) p.295-336(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The European Artificial Intelligence Strategy: Implications and Challenges for Digital Health
(
- Contribution to journal › Article
-
Mark
Denmark
2020) p.113-128(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
SWEDEN’s Response to COVID-19: A tale of trust, recommendations, and odorous nudges: Available at: https://blog.petrieflom.law.harvard.edu/2020/05/12/sweden-global-responses-covid19/
2020)(
- Other contribution › Miscellaneous
-
Mark
Regulatory responses to medical machine learning
(
- Contribution to journal › Article
-
Mark
The EU-US Privacy Shield Regime for Cross-Border Transfers of Personal Data under the GDPR: What are the legal challenges and how might these affect cloud-based technologies, big data, and AI in the medical sector?
(
- Contribution to journal › Article
-
Mark
Establishing the First International Genetic Discrimination Observatory
(
- Contribution to journal › Article
-
Mark
Clinical trial data transparency and GDPR compliance: Implications for data sharing and open innovation
2020) In Science and Public Policy(
- Contribution to journal › Article
-
Mark
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
(
- Contribution to journal › Article
-
Mark
Social, cultural and economic aspects of antimicrobial resistance
(
- Contribution to journal › Article
-
Mark
Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countries
(
- Contribution to journal › Article
-
Mark
At the Epicentre of COVID-19 - the Tragic Failure of the Global Supply Chain for Medical Supplies
2020) In Frontiers in Public Health(
- Contribution to journal › Article
-
Mark
Lost on the High Seas without a Safe Harbor or a Shield? Navigating Cross-Border Data Transfers in the Pharmaceutical Sector After Schrems II Invalidation of the EU-US Privacy Shield
(
- Contribution to journal › Article
- 2019
-
Mark
How does emerging patent case law in the US and Europe affect precision medicine?
(
- Contribution to journal › Article
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part I)
2019)(
- Other contribution › Miscellaneous
-
Mark
Homomorphic Encryption: The ‘Holy Grail’ for Big Data Analytics & Legal Compliance in the Pharmaceutical and Healthcare Sector?
(
- Contribution to journal › Article
-
Mark
The Legal Dimensions of Big Data, Artificial Intelligence and Machine Learning in Pharmaceutical Innovation (original title in accepted version): Editorial to special issue of the European Pharmaceutical Law Review on "Big Data, AI & Machine Learning in Pharmaceutial Innovation"
(
- Contribution to journal › Article
-
Mark
AIPPI Report for Denmark on Plausibility in Patent Law: AIPPI 2019 - 2019 Study Questions - Plausibility
2019)(
- Book/Report › Book
-
Mark
The problem with antibiotics
(
- Contribution to journal › Article
-
Mark
Is Data Sharing Caring Enough About Patient Privacy?: Part I: The Background
2019)(
- Other contribution › Miscellaneous
-
Mark
What lurks in the shadows of the openness hyperbole for biopharmaceuticals?
2019) In Drug Development Research(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine
(
- Contribution to journal › Article
-
Mark
An Update on Research- & Bolar exemptions in the U.S. and Europe: Unsolved questions and new developments in an increasingly important area of law
(
- Contribution to journal › Article
-
Mark
Global Genes, Local Concerns: Legal, Ethical and Scientific Challenges in International Biobanking
2019)(
- Book/Report › Book
-
Mark
Much ado about something. Legal, ethical, and scientific challenges in international biobanking and translational exploitation
2019) 1.(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Shadow health records meet new data privacy laws
(
- Contribution to journal › Article
-
Mark
An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
(
- Contribution to journal › Article
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part 2)
2019)(
- Other contribution › Miscellaneous
- 2018
-
Mark
Big Data and intellectual property rights in the health and life sciences
2018) p.311-323(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A Ray of Light in Muddy Waters? -The CJEU rules on combination SPCs in C-121/17 Teva v Gilead
(
- Contribution to journal › Article
-
Mark
How much is too much?- Defining the Metes and Bounds of Excessive Pricing in the Pharmaceutical Sector
(
- Contribution to journal › Article
-
Mark
Challenges for the sustainability of university-run biobanks
(
- Contribution to journal › Article
-
Mark
Will the EPO’s Enlarged Board of Appeal hear the Broad's CRISPR case?
2018) In Life Sciences Intellectual Property Review (LSIPR)(
- Contribution to journal › Article
-
Mark
Patentability Standards for Follow-on Pharmaceutical Innovation
(
- Contribution to journal › Article
-
Mark
Big Data in the Health and Life Sciences: What Are the Challenges for European Competition Law and Where Can They Be Found?
2018) In CEIPI / ICTSD Publication Series on Global Perspectives and Challenges for the Intellectual Property System p.121-130(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Clearing a way through the CRISPR patent jungle
2018) In Life Sciences Intellectual Property Review (LSIPR)(
- Contribution to journal › Article
-
Mark
Reap what you sow! - But what about SPC squatting?
(
- Contribution to journal › Article
- 2017
-
Mark
Patenting Human Genes in Europe: and how it compares to the US and Australia
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Innovation and Intellectual Property Policies in European Research Infrastructure Consortia - PART I: The Case of the European Spallation Source ERIC
(
- Contribution to journal › Article
- 2016
-
Mark
Separating sheep from goats : A European view on the patent eligibility of biomedical diagnostic methods
(
- Contribution to journal › Article
-
Mark
Fighting Falsified Medicines with Paperwork – A Historic Review of Danish Legislation Governing Distribution of Medicines
(
- Contribution to journal › Article
-
Mark
Reconciling IPRs and openness in biobanking
(
- Contribution to journal › Article
-
Mark
Standards, Data Exchange and Intellectual Property Rights in Systems Biology
(
- Contribution to journal › Article
-
Mark
The Industrial Application Requirement for Biotech Inventions in Light of Recent EPO and UK Case Law: A Plausible Approach or a Mere "Hunting Licence"?
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2015
-
Mark
The Evolution of the CJEU’s Case Law on Stem Cell Patents : Context, Outcome and Implications of Case C‑364/13 International Stem Cell Corporation
(
- Contribution to journal › Article
-
Mark
The Impact of Broccoli II & Tomato II on European patents in conventional breeding, GMO’s and Synthetic Biology : The grand finale of a juicy patents tale?
(
- Contribution to journal › Article
-
Mark
Will clinical trial data disclosure reduce incentives to develop new uses of drugs?
(
- Contribution to journal › Article
-
Mark
Life after Myriad: the uncertain future of patenting biomedical innovation and personalised medicine in an international context
(
- Contribution to journal › Article
-
Mark
Enforcing patents in the era of 3D printing
(
- Contribution to journal › Article
-
Mark
IPRs in Biobanking: Risks and Opportunities for Translational Research
(
- Contribution to journal › Article
-
Mark
Standardization, IPRs and open innovation in synthetic biology
2015) p.34-66(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A “ray of hope” for European stem cell patents or “out of the smog into the fog”?: The CJEU decision in C-364/13 and how it compares to recent US developments.(under review)
2015) In Biotechnology Law Report(
- Contribution to journal › Article
-
Mark
Synthetic biology and intellectual property rights: Six recommendations
(
- Contribution to journal › Article
- 2014
-
Mark
Book Review: Drexl, J., Lee, N. (2013). Pharmaceutical Innovation, Competition and Patent Law : A Trilateral Perspective. Edward Elgar Publishing
(
- Contribution to journal › Review (Book/Film/Exhibition/etc.)
-
Mark
The ”opt out” and “opt in” provisions in the Unified Patent Court Agreement – Impact and strategies for European patent portfolios
(
- Contribution to journal › Article
-
Mark
Legal aspects of biobanking as key issues for personalized medicine and translational exploitation
(
- Contribution to journal › Article
- 2012
-
Mark
Assessing the Inventiveness of Bio-Pharmaceuticals under European and US Patent Law - A comparative study with special emphasis on DNA- and protein-related inventions
2012)(
- Thesis › Doctoral thesis (monograph)
-
Mark
The US Supreme Court in Mayo v Prometheus - taking the fire from or to biotechnology and personalized medicine?
(
- Contribution to journal › Article
-
Mark
Standing on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO--Part II1
(
- Contribution to journal › Article
-
Mark
What intent, whose intent and to what extent?: The Knowledge requirement in indirect patent infringement
(
- Contribution to journal › Article
-
Mark
The industrial application requirement for biotech inventions in light of recent EPO & UK case law:: A plausible "hunting license"?"
(
- Contribution to journal › Article
- 2011
-
Mark
US Patent Eligibility in the Wake of Bilski v Kappos: "Business as Usual" in an Age of New Technologies?
(
- Contribution to journal › Article
-
Mark
Standing on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO--Part I
(
- Contribution to journal › Article
-
Mark
Contribution to case law summaries and comments: Tri-lingual
2011)(
- Book/Report › Book
-
Mark
Standing on shaky ground: US patent-eligibility of isolated DNA and genetic diagnostics after AMP v USPTO – Part I
(
- Contribution to journal › Article
- 2010
-
Mark
Refusal to supply in the EU pharmaceutical sector under the rule of reason
(
- Contribution to journal › Article
-
Mark
Meanwhile on the Other Side of the Pond: Why Biopharmaceutical Inventions that Were'Obvious to Try'Still Might Be Non-Obvious--Part I
(
- Contribution to journal › Article
- 2009
-
Mark
“Restoring the balance: The patentability of DNA-related technology in the US and Europe”
2009) Scholarship speech prepared for the AWAPATENT Foundation for the Promotion of Scientific Research in the Area of Intellectual Property Rights. p.1-10(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Meanwhile on the Other Side of the Pond: Why Biopharmaceutical Inventions that Were “Obvious to Try” Still Might Be Non-Obvious – Part I
2009) In Chicago-Kent Journal of Intellectual Property (forthcoming)(
- Contribution to journal › Article
-
Mark
The rule of reason under Article 82 EC After Sot Lelos kai Sia
2009)(
- Working paper/Preprint › Working paper
- 2008
-
Mark
The US Examination of Nonobviousness After KSR v. Teleflex with Special Emphasis on DNA-Related Inventions
(
- Contribution to journal › Article
-
Mark
Es bleibet dabei: Eine schwedische Stellungnahme zur europäischen Debatte über den absoluten Erzeugnisschutz bei der DNA Patentierung
(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar? - Del II (When does European patent law regard a biotechnological invention as complete and having an industrial application?)
(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar?- Del I (When does US patent law regard a biotechnological invention as complete and useful?)
(
- Contribution to journal › Article
-
Mark
Is In re Deuel still the law of the land? The US examination of nonobviousness after KSR v. Teleflex with special emphasis on DNA related inventions
2008) In Historielärarnas Förenings Årsskrift(
- Contribution to journal › Article
-
Mark
Standing in the shadows of Brüstle: ordre public & the patentability of human embryonic stem cell technology in Germany and at the EPO
2008) In Historielärarnas Förenings Årsskrift(
- Contribution to journal › Article
-
Mark
Zur Zulässigkeit von Feststellungsklagen im US Lizensrecht nach den Entscheidungen in MedImmune und SanDisk
2008) In GRUR International (Gewerblicher Rechtsschutz und Urheberrecht)(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar?--Del 1:--Om nyare utvecklingar kring kravet på’industrial application’och’utility’för gen-och proteinrelaterade uppfinningar i USA och Europa
(
- Contribution to journal › Article
-
Mark
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar? – Del 2: Om nyare utvecklingar kring kravet på ’industrial application’ och ’utility’ för gen- och proteinrelaterade uppfinningar i USA och Europa
(
- Contribution to journal › Article
-
Mark
Es bleibet dabei: Eine schwedische Stellungnahme zur europäischen Debatte über den absoluten Erzeugnisschutz bei der DNA-Patentierung--Teil 2
(
- Contribution to journal › Article
-
Mark
Es bleibet dabei: Eine schwedische Stellungnahme zur europäischen Debatte über den absoluten Erzeugnisschutz bei der DNA-Patentierung – Teil 1
(
- Contribution to journal › Article
-
Mark
The US Examination of Nonobviousness after KSR vs. Teleflex with Special Emphasis on DNA-Related Inventions
(
- Contribution to journal › Article
- 2007
-
Mark
Res judicata in the court of justice case-law: Balancing legal certainty with legality?
(
- Contribution to journal › Article
-
Mark
Obesvarade frågor rörande patent på datorrelaterade uppfinningar och affärsmetoder? (Unanswered questions concerning patents on computer related inventions and business methods?)
(
- Contribution to journal › Article
-
Mark
Res judicata i EG –domstolens rättspraxis: en avvägning mellan rättssäkerhet och lagenlighet
(
- Contribution to journal › Article
-
Mark
Obesvarade frågor rörande patent på datorrelaterade uppfinningar och affärsmetoder?: Reflektioner kring Alain Pompidous brev till Lord Justice Jacob
(
- Contribution to journal › Article
- 2006
-
Mark
Purpose-bound product patents for human DNA sequences? Discussing scope of protection issues in the light of the German implementation of the Biotech directive
2006) Legal Aspects of Biotechnology in Europe(
- Contribution to conference › Paper, not in proceeding
-
Mark
Purpose-bound product patents for human DNA sequences? Discussing scope of protection issues in the light of national implementations of the Biotech directive
2006) IP and Innovation in Bioscience, 2006(
- Contribution to conference › Paper, not in proceeding
- 2005
-
Mark
Patenting human DNA sequences in Europe and the US - A comparative analysis of patentability requirements for nucleic acid sequences with special emphasis on novelty and inventive step
2005)(
- Thesis › Licentiate thesis
-
Mark
Patenting Human DNA sequences in Europe and the U.S.: A comparative analysis of patentability requirements for nucleic acid sequences
2005)(
- Book/Report › Book